Stock Quote
Pharmacyclics, Inc. (PCYC.W) (NASD ADF)
$1.82
19 Nov 2009
-2.67%
$1.87
$1.82
100
$1.82
$1.82
$2.41
$0.57
1.28
21,580
PCYC.W
More News
| Press Releases
| Key Developments
| Name | Current Position | Compensation |
|---|---|---|
| Duggan, Robert | Chairman of the Board, Chief Executive Officer | -- |
| Erdtmann, Rainer | Vice President - Finance and Administration, Secretary | -- |
| Buggy, Joseph | Vice President - Research | 282,220 |
Profile
Pharmacyclics Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing small-molecule drugs for the treatment of immune mediated disease and cancer. Its pharmaceutical drug development candidates are synthetic small-molecules designed to focus key biochemical... Full Description
Company Address
Pharmacyclics, Inc.
995 East Arques Avenue
Sunnyvale CA 94085
P: +1408.7740330
F: +1408.7740340
995 East Arques Avenue
Sunnyvale CA 94085
P: +1408.7740330
F: +1408.7740340
Analyst Research
Performance of Key Competitors
| Company | Price | Change |
|---|---|---|
| Schering-Plough Corporation | -- | -- |
| Elan Corporation, plc | €4.25 | -0.11 |
| Allos Therapeutics, Inc. | $6.11 | -0.05 |
| PCYC.W | Industry | |
|---|---|---|
| P/E(TTM) | -- | 12.80 |
| P/S(TTM) | -- | 29.90 |
| ROI(TTM) | -119.34 | 2.35 |
| ROE(TTM) | -131.10 | 3.59 |
| Consensus Recommendation | Outperform |
|---|---|
| EPS Est. (Current Period) | -0.08 |
| EPS Est. (Current Year) | -0.88 |
| Total Revenue | $0.00M |
| Net Income | $-4.84M |
| EPS | $-0.12 |
